https://repositorio.ufu.br/handle/123456789/5158 2026-09-30T16:16:09Z 2026-09-30T16:16:09Z https://repositorio.ufu.br/handle/123456789/50383 2026-09-23T06:24:41Z 2026-06-26T00:00:00Z

Title: Potencial terapêutico de diferentes marcas de neurotoxina botulínica para tratamento de dor orofacial em humanos: uma revisão da Literatura Abstract: Chronic orofacial pain, including temporomandibular disorders (TMDs), myofascial pain, trigeminal neuralgia, and occipital neuralgia, represents a frequent therapeutic challenge in clinical practice, often exhibiting limited responsiveness to conventional treatments. In this context, botulinum toxin type A (BTX-A) has emerged as a promising therapeutic alternative. However, despite the wide availability of different commercial formulations, there is still no standardization regarding dosages, treatment protocols, or conversion ratios among products, which may influence clinical outcomes. Therefore, this study conducted a comprehensive literature review using the PubMed, Scopus, Web of Science, EMBASE, LILACS, and Google Scholar databases to identify human clinical studies investigating the use of BTX-A for the management of orofacial pain. Animal studies, reviews, study protocols, commentaries, conference abstracts, and case reports were excluded. Following duplicate removal using EndNote Web and Rayyan platforms, 1,069 records underwent screening by two independent reviewers, resulting in 84 eligible articles for full-text assessment. After the final selection process, 32 studies were included for in-depth analysis. The findings suggest that different botulinum toxin type A formulations—including OnabotulinumtoxinA (Botox®), AbobotulinumtoxinA (Dysport®), IncobotulinumtoxinA (Xeomin®), as well as products such as Hengli®, Botulax®, LetibotulinumtoxinA, and LanbotulinumtoxinA—demonstrate significant efficacy in reducing pain intensity, improving Visual Analog Scale (VAS) scores, decreasing the frequency of painful episodes, and enhancing patients’ quality of life. The most frequently investigated conditions were myofascial pain and TMD (18 studies, 688 patients), trigeminal neuralgia (14 studies, 700 patients), and occipital neuralgia (2 studies, 14 patients). Efficacy was consistently observed, particularly in myofascial pain/TMD and trigeminal neuralgia, whereas evidence for occipital neuralgia, although promising, remains limited. Regarding safety, BTX-A exhibited a favorable profile, with adverse events generally being mild and transient. Reported side effects included dysphagia, speech difficulties, facial asymmetry, muscle weakness, as well as isolated cases of hematoma, local erythema, xerostomia, diplopia, and headache. In conclusion, botulinum toxin type A appears to be an effective and safe therapeutic option for the management of chronic orofacial pain, particularly myofascial pain/TMD and trigeminal neuralgia. Nevertheless, methodological heterogeneity, small sample sizes, and the lack of standardization among different formulations continue to limit the comparability of findings. Further randomized controlled trials with larger sample sizes and standardized treatment protocols are required to establish more robust evidence and support clinical guidelines.

2026-06-26T00:00:00Z https://repositorio.ufu.br/handle/123456789/50359 2026-09-22T06:19:41Z 2026-08-26T00:00:00Z

Title: Manifestações orais de doenças imunomediadas: evidências clínicas e epidemiológicas de um serviço de referência regional Abstract: This study addresses immune-mediated diseases with oral manifestations, a heterogeneous group of conditions that significantly impact patients' quality of life and pose diagnostic challenges due to overlapping clinical features among different diseases. The research was conducted at a regional referral center, the Dental Hospital of the Federal University of Uberlândia, and comprised two complementary investigations. The first consisted of a retrospective observational analysis of the clinical, demographic, and therapeutic characteristics of patients diagnosed with oral lichen planus. The second explored the coexistence of psoriasis and oral pemphigus vulgaris, discussing potential underlying immunopathological mechanisms. Together, these studies highlight the importance of clinicopathological correlation, multidisciplinary management, and longitudinal follow-up in the care of patients with oral immune-mediated diseases, contributing to the improvement of diagnostic and therapeutic strategies within the Brazilian Unified Health System.

2026-08-26T00:00:00Z https://repositorio.ufu.br/handle/123456789/50345 2026-09-22T06:19:26Z 2026-03-04T00:00:00Z

Title: Avaliação da atividade antimicrobiana de bactérias odontopatogênicas por meio da inserção de nióbio em dentifrício fluoretado Abstract: Dental caries is a multifactorial disease strongly associated with the presence of cariogenic bacteria, especially Streptococcus mutans, Streptococcus mitis, and Streptococcus oralis, which justifies the search for oral care products with potential antimicrobial activity. The incorporation of bioactive metals into dental biomaterials has been widely investigated as a strategy to enhance dental biofilm control, with niobium standing out due to its high chemical stability and potential antimicrobial activity. Nevertheless, studies systematically evaluating the antimicrobial effects of niobium-derived compounds against odontopathogenic bacteria remain scarce, particularly when these compounds are incorporated into fluoridated dentifrices, thereby justifying the present investigation. This study assessed the antimicrobial activity of seven distinct niobium-derived compounds, both in their pure form and when incorporated into a commercial toothpaste formulation, against selected odontopathogenic bacteria. The evaluations included the determination of the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) using the broth microdilution assay, in addition to complementary analysis by the agar diffusion method. A selective inhibitory and bactericidal effect of the niobium compounds was observed against Streptococcus mitis and Streptococcus oralis, whereas Streptococcus mutans did not exhibit susceptibility at the tested concentrations. In the agar diffusion assay, the incorporation of 10% niobium pentoxide and niobium nitride into the commercial dentifrice resulted in increased inhibition zones against S. mitis compared with the dentifrice alone. However, these compounds did not enhance antimicrobial activity against S. mutans or S. oralis. These findings suggest species-dependent antimicrobial activity, indicating selective potential and the need for further investigations for clinical application.

2026-03-04T00:00:00Z https://repositorio.ufu.br/handle/123456789/50339 2026-09-19T06:24:21Z 2026-07-27T00:00:00Z

Title: Terapia a laser de baixa intensidade e gel à base de fluoreto, sílica e cálcio para o controle da hipersensibilidade dentinária: estudo clínico randomizado controlado. Abstract: The present study aimed to evaluate the isolated and combined effects of a fluoride/silica/calcium (FSC) gel and low-level laser therapy (LLLT) in the management of dentin hypersensitivity (DH). Forty-five patients with DH presenting at least one tooth with exposed cervical dentin on the buccal surface were included. DH was confirmed by a positive response of ≥40 mm on the Visual Analog Scale (VAS) following air and water stimulation. Participants were randomly allocated to three groups: FSC (fluoride/silica/calcium gel), LLLT (low-level laser therapy), and FSC/LLLT (combined therapy). The FSC and FSC/LLLT groups received three in-office applications of the FSC gel at 72-hour intervals, combined with home use of the gel for two months, followed by replacement with a fluoride/silica gel (without the calcium booster) for three months. The LLLT and FSC/LLLT groups received laser applications during the first three treatment sessions and at follow-up visits after 7 days, 15 days, 1 month, and 3 months. Pain was assessed following evaporative and tactile stimuli using the VAS and the Schiff Cold Air Sensitivity Scale at baseline, immediately after each treatment session, and at the 7-day, 15-day, 1-month, and 3-month follow-up visits. Oral health-related quality of life was assessed using the Dentine Hypersensitivity Experience Questionnaire (DHEQ-15) at baseline and throughout the follow-up period. All groups exhibited an immediate reduction in pain elicited by evaporative stimulation after the first intervention, with no significant differences among treatments. A similar pattern was observed after the second and third treatment sessions. Compared with baseline, all groups showed a gradual reduction in pain over time. For tactile sensitivity and Schiff scale assessments, only the LLLT group demonstrated significant reductions immediately after the first three treatment sessions, whereas all groups exhibited significant improvements over time. Oral health-related quality of life also improved in all groups. It can be concluded that both the FSC gel and LLLT were effective in reducing pain and improving the quality of life of patients with DH. However, the combination of these therapies did not provide additional benefits compared with either treatment alone, suggesting similar clinical efficacy among the treatment approaches.

2026-07-27T00:00:00Z